https://orcid.org/0000-0001-7435-5726
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Edgar Carnero Contentti & Jorge Correale. (2022) Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Drug Design, Development and Therapy 16, pages 3473-3490.
Read now
Read now
Articles from other publishers (27)
Olivier Nicolas, Patricia Moliner, Patrick Soubayrol, Olivier Vitse, Sebastien Roy, Marie-José Cabanis, Tim Turner, Sylvie Klieber, Stephane Muccio, Catherine Arabeyre & Priscilla Brun. (2023) Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity. Clinical Drug Investigation 43:8, pages 653-665.
Crossref
Crossref
Joke Temmerman, Sebastiaan Engelborghs, Maria Bjerke & Miguel D’haeseleer. (2023) Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review. Frontiers in Immunology 14.
Crossref
Crossref
Julia Krämer, Amit Bar-Or, Timothy J. Turner & Heinz Wiendl. (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology 19:5, pages 289-304.
Crossref
Crossref
Lucia Gozzo, Giovanni Luca Romano, Serena Brancati, Laura Longo, Daniela Cristina Vitale & Filippo Drago. (2023) The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries. Frontiers in Pharmacology 14.
Crossref
Crossref
Chi Chiu Mok. (2023) Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline. Drugs 83:6, pages 479-496.
Crossref
Crossref
卓如 周. (2023) Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma. Advances in Clinical Medicine 13:01, pages 1083-1091.
Crossref
Crossref
Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, Barry Hendin & Timothy Vollmer. (2022) High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 36:12, pages 1285-1299.
Crossref
Crossref
Anastasia Geladaris, Sebastian Torke & Martin S. Weber. (2022) Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?. CNS Drugs 36:10, pages 1019-1030.
Crossref
Crossref
Shane Arsenault, Rochelle Y. Benoit, Fraser Clift & Craig S. Moore. (2022) Does the use of the Bruton Tyrosine Kinase Inhibitors and the C-kit Inhibitor Masitinib Result in Clinically Significant Outcomes Among Patients with Various Forms of Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, pages 104164.
Crossref
Crossref
Nicolas Collongues, Guillaume Becker, Valérie Jolivel, Estelle Ayme-Dietrich, Jérôme de Seze, Fabien Binamé, Christine Patte-Mensah, Laurent Monassier & Ayikoé Guy Mensah-Nyagan. (2022) A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. Neurology and Therapy 11:3, pages 981-1042.
Crossref
Crossref
Liza Rijvers, Jamie van Langelaar, Laurens Bogers, Marie-José Melief, Steven C. Koetzier, Katelijn M. Blok, Annet F. Wierenga-Wolf, Helga E. de Vries, Jasper Rip, Odilia B.J. Corneth, Rudi W. Hendriks, Roland Grenningloh, Ursula Boschert, Joost Smolders & Marvin M. van Luijn. (2022) Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. JCI Insight 7:16.
Crossref
Crossref
Debasis Das, Jingbing Wang & Jian Hong. (2022) Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially
Targeting BTK C481S Mutation- Recent Developments and Perspectives. Current Topics in Medicinal Chemistry 22:20, pages 1674-1691.
Crossref
Crossref
Pedro Mendes‐Bastos, Ana Brasileiro, Pavel Kolkhir, Stefan Frischbutter, Jörg Scheffel, Sherezade Moñino‐Romero & Marcus Maurer. (2022) Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions. Allergy 77:8, pages 2355-2366.
Crossref
Crossref
Jiwon Oh & Amit Bar-Or. (2022) Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology 18:8, pages 466-475.
Crossref
Crossref
Bruce A.C. Cree, Hans-Peter Hartung & Michael Barnett. (2022) New drugs for multiple sclerosis: new treatment algorithms. Current Opinion in Neurology 35:3, pages 262-270.
Crossref
Crossref
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, Gabriel Andrieș, Călin Căinap & Vasile Chiș. (2022) Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. International Journal of Molecular Sciences 23:9, pages 5023.
Crossref
Crossref
Joachim Havla & Reinhard Hohlfeld. (2022) Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics 19:3, pages 774-784.
Crossref
Crossref
Monica Margoni, Paolo Preziosa, Massimo Filippi & Maria A. Rocca. (2021) Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. Journal of Neurology 269:3, pages 1316-1334.
Crossref
Crossref
Magdalena Kołodziej, Karolina Chrabąszcz, Ewa Pięta, Natalia Piergies, Julia Rudnicka-Czerwiec, Halina Bartosik-Psujek, Czesława Paluszkiewicz, Marian Cholewa & Wojciech M. Kwiatek. (2022) Spectral signature of multiple sclerosis. Preliminary studies of blood fraction by ATR FTIR technique. Biochemical and Biophysical Research Communications 593, pages 40-45.
Crossref
Crossref
David J. Donnelly, Sean Preshlock, Tanpreet Kaur, Tritin Tran, Thomas C. Wilson, Karim Mhanna, Bradford D. Henderson, Daniel Batalla, Peter J. H. Scott & Xia Shao. (2022) Synthesis of Radiopharmaceuticals via “In-Loop” 11C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase. Frontiers in Nuclear Medicine 1.
Crossref
Crossref
Bruno Tasso, Andrea Spallarossa, Eleonora Russo & Chiara Brullo. (2021) The Development of BTK Inhibitors: A Five-Year Update. Molecules 26:23, pages 7411.
Crossref
Crossref
Anton Lindberg, Amanda J. Boyle, Junchao Tong, Michael B. Harkness, Armando Garcia, Tritin Tran, Dongxu Zhai, Fang Liu, David J. Donnelly & Neil Vasdev. (2021) Radiosynthesis of [11C]Ibrutinib via Pd-Mediated [11C]CO Carbonylation: Preliminary PET Imaging in Experimental Autoimmune Encephalomyelitis Mice. Frontiers in Nuclear Medicine 1.
Crossref
Crossref
Jorge Correale, Mario Javier Halfon, Dominic Jack, Adrián Rubstein & Andrés Villa. (2021) Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Multiple Sclerosis and Related Disorders 56, pages 103264.
Crossref
Crossref
Sining Zhu, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale & Ping Xie. (2021) Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Frontiers in Oncology 11.
Crossref
Crossref
Jorge Correale. (2021) BTK inhibitors as potential therapies for multiple sclerosis. The Lancet Neurology 20:9, pages 689-691.
Crossref
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Crossref
Berenice Anabel Silva, Esteban Miglietta & Carina Cintia Ferrari. (2021) Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients. Multiple Sclerosis and Related Disorders 50, pages 102845.
Crossref
Crossref